| Size | Price | Stock | Qty |
|---|---|---|---|
| 10mg |
|
||
| Other Sizes |
| Targets |
The parent compound N-Methylnicotinamide targets nicotinamide N-methyltransferase (NNMT), the enzyme responsible for its synthesis. It also acts as an inhibitor of ADP-ribosylation and has antithrombotic effects via production/release of prostacyclin, which inhibits arterial thrombosis. Additionally, it is involved in the NAD+ metabolic pathway and is a substrate for renal organic cation transporters. The deuterium-labeled version is not itself used for activity studies but serves as a tracer.
|
|---|---|
| ln Vitro |
Drug compounds have included stable heavy isotopes of carbon, hydrogen, and other elements, mostly as quantitative tracers while the drugs were being developed. Because deuteration may have an effect on a drug's pharmacokinetics and metabolic properties, it is a cause for concern [1].
The parent compound N-Methylnicotinamide is an endogenous metabolite with antithrombotic activity. It inhibits ADP-ribosylation and stimulates prostacyclin production. In primary cultures of rat cerebellar granule cells, N-methylnicotinamide inhibits NMDA- and glutamate-evoked calcium uptake, suggesting neuroprotective potential. However, the deuterium-labeled version (N-Methylnicotinamide-d4) is not used to measure biological activity but rather as an internal standard. |
| ln Vivo |
The parent compound N-Methylnicotinamide exhibits antithrombotic effects in vivo by inhibiting arterial thrombosis development through production/release of prostacyclin. It also has neuroprotective potential in acute excitotoxicity models. The deuterium-labeled version (N-Methylnicotinamide-d4) is not intended for in vivo activity studies; its use is limited to analytical quantification.
|
| Enzyme Assay |
For non-cellular assays, N-Methylnicotinamide-d4 is dissolved in methanol or water to prepare stock solutions (1 mg/mL). For LC-MS/MS analysis, the compound is used as an internal standard. Calibration curves are generated using unlabeled N-Methylnicotinamide (0.1-1000 ng/mL) with a fixed concentration of N-Methylnicotinamide-d4 (e.g., 50 ng/mL). Chromatographic separation is achieved on a C18 column with mobile phase of 0.1% formic acid in water and acetonitrile (gradient elution).
|
| Cell Assay |
For cell-based assays, primary cultures of rat cerebellar granule cells (CGCs) are prepared from 7-day-old rat pups. Cells are seeded in poly-L-lysine-coated plates (1×10⁵ cells/well) in Neurobasal medium with B27 supplement. After 7 days in vitro, cells are treated with N-methylnicotinamide (0.1-100 uM) for 30 minutes before exposure to NMDA (50 uM) or glutamate (100 uM) for 10 minutes. Calcium uptake is measured using ⁴⁵Ca2+ or Fluo-4 AM fluorescence. The deuterated analog (d4) can be used to quantify MNA levels in cell lysates by LC-MS.
|
| Animal Protocol |
For in vivo animal experiments, rodent models (e.g., mice or rats) are used to study thrombosis. Arterial thrombosis is induced by ferric chloride (FeCl3) or photochemical injury. N-methylnicotinamide is administered intravenously (IV) or orally at doses of 10-50 mg/kg prior to injury. Blood flow is monitored by Doppler flow probe. Prostacyclin levels are measured by ELISA. The deuterium-labeled version (N-Methylnicotinamide-d4) is not used in these experiments but can be used as a tracer for pharmacokinetic studies.
|
| ADME/Pharmacokinetics |
N-Methylnicotinamide-d4 is a deuterium-labeled compound where four hydrogen atoms are replaced with deuterium. This modification does not significantly alter chemical properties but improves stability and allows for precise quantification by LC-MS/MS. It is used as an internal standard for measuring N-methylnicotinamide levels in biological samples. Deuteration may affect pharmacokinetics and metabolic properties, making it useful for tracing studies.
|
| Toxicity/Toxicokinetics |
As a stable isotope-labeled compound, N-Methylnicotinamide-d4 is non-toxic at typical research concentrations (ug/mL). Standard safety guidelines for handling organic compounds should be followed. No toxicity studies have been specifically conducted for the deuterated version. The parent compound (N-Methylnicotinamide) is an endogenous metabolite and is generally considered safe at physiological levels.
|
| References | |
| Additional Infomation |
N-Methylnicotinamide-d4 is an analytical standard and research tool, not an approved drug. It has no clinical trials for therapeutic use. Its primary application is in analytical chemistry and metabolomics, specifically for quantifying N-methylnicotinamide in biological samples. The compound is used in studies of nicotinamide metabolism, NAD+ pathways, and renal transporter function. It is not intended for human therapeutic use.
|
| Molecular Formula |
C7H4D4N2O
|
|---|---|
| Molecular Weight |
140.18
|
| Exact Mass |
140.088
|
| CAS # |
2708278-64-0
|
| Related CAS # |
N-Methylnicotinamide;114-33-0
|
| PubChem CID |
129010204
|
| Appearance |
White to off-white solid powder
|
| LogP |
0
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
2
|
| Rotatable Bond Count |
1
|
| Heavy Atom Count |
10
|
| Complexity |
125
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
C1([2H])C(C(=O)NC)=C(N=C([2H])C=1[2H])[2H]
|
| InChi Key |
ZYVXHFWBYUDDBM-QFFDRWTDSA-N
|
| InChi Code |
InChI=1S/C7H8N2O/c1-8-7(10)6-3-2-4-9-5-6/h2-5H,1H3,(H,8,10)/i2D,3D,4D,5D
|
| Chemical Name |
2,4,5,6-tetradeuterio-N-methylpyridine-3-carboxamide
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 7.1337 mL | 35.6684 mL | 71.3369 mL | |
| 5 mM | 1.4267 mL | 7.1337 mL | 14.2674 mL | |
| 10 mM | 0.7134 mL | 3.5668 mL | 7.1337 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
